Tirzepatide (API – CAS 2023788-19-2)

Tirzepatide · CAS 2023788-19-2 · GLP-1 / Weight Management

Overview

Tirzepatide is a widely used active pharmaceutical ingredient (API) in the GLP-1 / Weight Management therapeutic category. It is supplied as a bulk pharmaceutical-grade material manufactured to meet stringent international quality standards.

Therapeutic Application

Tirzepatide is a dual GIP and GLP-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity or overweight.

Specifications

• CAS Number: 2023788-19-2
• Appearance: White to off-white crystalline powder
• Typical Assay/Purity: ≥ 99.0%
• Common Pharmacopeial Grades: USP, EP, BP, IP
• Storage: Store in a cool, dry place, away from light
• Shelf Life: Typically 24 months under recommended storage conditions

Regulatory & Compliance

Intravarsity adheres to WHO-GMP manufacturing practices, ensuring that Tirzepatide is produced in compliance with international quality standards. Availability of regulatory documents such as USDMF, CEP, and EU-GMP certificates, along with Certificates of Analysis (COA) and Certificates of Suitability (COS), is subject to inquiry.

Packaging & Shipping

Tirzepatide is packaged in 25kg HDPE drums with double LDPE liners, palletized for secure transport. All necessary export documentation is provided, facilitating shipping to key markets including USA, EU, UK, Australia.

Common Use Cases & Finished Dosage Forms

This API is typically incorporated into various dosage forms including:

• Tablets
• Capsules
• Injectable solutions

Ordering Information

The minimum order quantity (MOQ) for Tirzepatide is subject to inquiry. Interested parties are encouraged to request a Certificate of Analysis (COA) and a quote via this listing. For further inquiries, please contact Intravarsity directly.